Jianfu Zhao
A5050842617- CAR-T cell therapy research
- PI3K/AKT/mTOR signaling in cancer
- Cancer Research and Treatments
- Nanoplatforms for cancer theranostics
- Ubiquitin and proteasome pathways
- Protein Degradation and Inhibitors
- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- Laser-Ablation Synthesis of Nanoparticles
- Selenium in Biological Systems
- Biosimilars and Bioanalytical Methods
First Affiliated Hospital of Jinan University
2022-2025
Jinan University
2024
Abstract Background Pucotenlimab is a novel recombinant humanized anti-PD-1 (Programmed death-1) monoclonal antibody, which belongs to the human IgG4/kappa subtype, and can selectively block binding of PD-1 with its ligands PD-L1 PD-L2. Methods In this phase 2 trial, patients locally advanced or metastatic melanoma who had failed conventional treatment (chemotherapy, targeted therapy, interferon, IL-2, et al.) were recruited. The administrated 3 mg/kg every weeks until disease progression,...
Radiation therapy is a cornerstone of prostate cancer (PCa) treatment. However, its limited tumor sensitivity and severe side effects restrict clinical utility. Lentinan-functionalized selenium nanoparticles (LET-SeNPs) have shown promise in enhancing radiotherapy exhibiting antitumor activity. In this study, we investigated the sensitization mechanism LET-SeNPs PCa. Our results demonstrate that combination X-ray (4 Gy) significantly inhibited growth colony formation PCa cells by inducing...
Nuclear protein of the testis (NUT) carcinoma is a rare and highly aggressive malignancy characterized by rearrangement NUT midline family member 1 (NUTM1) gene. Nevertheless, standardized strategies for its diagnosis treatment remain unavailable, underscoring need expert consensus. To address this gap, we conducted systematic review to gather comprehensive information on from five databases: PubMed, Web Science, Embase, Cochrane Library, Ovid Medline. This consensus was collaboratively...
Abstract Background: Pucotenlimab is a novel recombinant humanized anti-PD-1 (Programmed death-1) monoclonal antibody, which belongs to the human IgG4/kappa subtype, and can selectively block binding of PD-1 with its ligands PD-L1 PD-L2. Methods: In this phase 2 trial, patients locally advanced or metastatic melanoma who had failed conventional treatment were recruited. The administrated 3 mg/kg every weeks until disease progression, intolerable toxicity, discontinuation for any other...